Why Is Esperion Therapeutics Stock Trading Higher Today?

Esperion Therapeutics Inc ESPR announced the presentation of results from two CLEAR Outcomes Study Late-Breakers at the European Society of Cardiology Congress 2023.

Bempedoic acid is indicated as an adjunct to diet and maximally tolerated statin therapy for heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C.

Treatment with bempedoic acid is associated with a risk reduction of 20% in total MACE-4 events (composite of major adverse cardiovascular events including non-fatal myocardial infarction, non-fatal stroke, coronary revascularization, and cardiovascular death), 17% in total MACE-3 events (composite of major adverse cardiovascular events including non-fatal myocardial infarction, non-fatal stroke and cardiovascular death), 31% in total myocardial infarctions, and 22% in total coronary revascularizations.

Composite of major adverse cardiovascular events including non-fatal myocardial infarction, non-fatal stroke, coronary revascularization, and cardiovascular death.

Of the 13,970 patients included in CLEAR Outcomes, 45.6% had diabetes, 41.5% were pre-diabetic, and 12.9% had normoglycemia. 

In this pre-specified analysis, bempedoic acid demonstrated a benefit in patients with diabetes at baseline, showing a 17% reduction in the risk of MACE-4 and a 20% reduction in the risk of MACE-3. 

In addition, bempedoic acid did not increase rates of new-onset diabetes in patients without diabetes and was generally comparable to placebo (11.1% vs. 11.5%, respectively). 

Finally, bempedoic acid did not increase HbA1c levels at 12 months or the end of the study in patients with pre-diabetes or normoglycemia.

Price Action: ESPR shares are up 15.90% at $1.60 on the last check Monday.